Efficacy and Safety of Banxia XieXin Decoction, a Blended Traditional Chinese Medicine, as Monotherapy for Patients With Advanced Hepatocellular Carcinoma

Abstract

Purpose: To explore a new therapeutic option for patients with hepatocellular carcinoma (HCC), the efficacy and safety of a group of traditional Chinese medicines (Banxia XieXin recipe) as monotherapy for patients with advanced HCC was studied. Materials and Methods: The study included 68 patients with advanced HCC from August 16,2016 to August 15,2019 for analysis. These eligible patients received treatment with Banxia XieXin recipe for at least 1 month. The primary endpoints were progression-free survival (PFS) and overall survival (OS). The secondary efficacy endpoints included objective response rate (ORR) and disease control rate (DCR). In addition, safety was also assessed. Results: The median treatment duration of these 68 patients was 10.3 months (range = 1.6-33.5 months), and follow-up is still ongoing. The median PFS was 6.07 months (95% confidence interval [CI] = 3.748-8.392 months), and the median OS was 12.60 months (95% CI = 8.019-17.181 months). The ORR was 10.3% and the DCR was 41.2%. In the subgroup analysis, the median OS in the transcatheter arterial chemoembolization (TACE) group was not reached, and the median OS in the NO TACE group was 11.30 months (95% CI = 3.219-19.381 months). In addition, no drug-related serious adverse events were observed during the study. Conclusion: This is the first clinical analysis of traditional Chinese medicine as a single treatment for advanced HCC. The obtained results are encouraging as they suggest that this panel of Chinese herbs is safe and it may be effective for patients with advanced HCC in a real-world clinical setting.

Banxia Xiexin Decoction Inhibits the Expression of PD-L1 Through Multi-Target and Multi-Pathway Regulation of Major Oncogenes in Gastric Cancer

“…Yan et al 5 showed that BXXX had a significant relieving effect on colon cancer in nude mice. Wang et al 15 evaluated the efficacy and safety of BXXX in advanced liver cancer treatment and found that BXXX could prolong the overall survival of liver cancer patients without obvious adverse reactions. So far, studies on the therapeutic potential of BXXX in GC have been insufficient as there is only one medical paper available on the literature database that is related to such subject.…”

Current Perspective of Traditional Chinese Medicines and Active Ingredients in the Therapy of Hepatocellular Carcinoma

“…Moreover, Wang et al conducted a clinical trial to evaluate the efficacy and safety of BXXX as monotherapy for patients with advanced HCC. 20 In the study, BXXX monotherapy exhibited the median progression-free survival (PFS) of 6.07 months, whereas sorafenib, the first-line treatment of advanced HCC, displayed the median PFS of 2.8 months in China. These findings suggested that the efficacy of BXXX may be superior to that of sorafenib in patients with advanced HCC, although this was not a direct comparison.…”

Banxia Xiexin decoction: A review on phytochemical, pharmacological, clinical and pharmacokinetic investigations

“…The results are promising since no drug-related serious adverse events were observed during the study and can be useful for treating patients with advanced HCC in a practical therapeutic environment. [78] 18. Application of BXD in treatment of adverse reactions of anticancer drugs For extensive-stage small cell lung carcinoma (SCLC), CPT-11 can be utilized as a first-line therapeutic medication in both first-line and second-line therapy.…”

“…The results are promising since no drug-related serious adverse events were observed during the study and can be useful for treating patients with advanced HCC in a practical therapeutic environment. [ 78 ]…”